Cargando…
Baseline exposure, antibody subclass, and hepatitis B response differentially affect malaria protective immunity following RTS,S/AS01E vaccination in African children
BACKGROUND: The RTS,S/AS01E vaccine provides partial protection against malaria in African children, but immune responses have only been partially characterized and do not reliably predict protective efficacy. We aimed to evaluate comprehensively the immunogenicity of the vaccine at peak response, t...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6208122/ https://www.ncbi.nlm.nih.gov/pubmed/30376866 http://dx.doi.org/10.1186/s12916-018-1186-4 |
_version_ | 1783366656780664832 |
---|---|
author | Ubillos, Itziar Ayestaran, Aintzane Nhabomba, Augusto J Dosoo, David Vidal, Marta Jiménez, Alfons Jairoce, Chenjerai Sanz, Hèctor Aguilar, Ruth Williams, Nana Aba Díez-Padrisa, Núria Mpina, Maximilian Sorgho, Hermann Agnandji, Selidji Todagbe Kariuki, Simon Mordmüller, Benjamin Daubenberger, Claudia Asante, Kwaku Poku Owusu-Agyei, Seth Sacarlal, Jahit Aide, Pedro Aponte, John J Dutta, Sheetij Gyan, Ben Campo, Joseph J Valim, Clarissa Moncunill, Gemma Dobaño, Carlota |
author_facet | Ubillos, Itziar Ayestaran, Aintzane Nhabomba, Augusto J Dosoo, David Vidal, Marta Jiménez, Alfons Jairoce, Chenjerai Sanz, Hèctor Aguilar, Ruth Williams, Nana Aba Díez-Padrisa, Núria Mpina, Maximilian Sorgho, Hermann Agnandji, Selidji Todagbe Kariuki, Simon Mordmüller, Benjamin Daubenberger, Claudia Asante, Kwaku Poku Owusu-Agyei, Seth Sacarlal, Jahit Aide, Pedro Aponte, John J Dutta, Sheetij Gyan, Ben Campo, Joseph J Valim, Clarissa Moncunill, Gemma Dobaño, Carlota |
author_sort | Ubillos, Itziar |
collection | PubMed |
description | BACKGROUND: The RTS,S/AS01E vaccine provides partial protection against malaria in African children, but immune responses have only been partially characterized and do not reliably predict protective efficacy. We aimed to evaluate comprehensively the immunogenicity of the vaccine at peak response, the factors affecting it, and the antibodies associated with protection against clinical malaria in young African children participating in the multicenter phase 3 trial for licensure. METHODS: We measured total IgM, IgG, and IgG(1–4) subclass antibodies to three constructs of the Plasmodium falciparum circumsporozoite protein (CSP) and hepatitis B surface antigen (HBsAg) that are part of the RTS,S vaccine, by quantitative suspension array technology. Plasma and serum samples were analyzed in 195 infants and children from two sites in Ghana (Kintampo) and Mozambique (Manhiça) with different transmission intensities using a case-control study design. We applied regression models and machine learning techniques to analyze immunogenicity, correlates of protection, and factors affecting them. RESULTS: RTS,S/AS01E induced IgM and IgG, predominantly IgG1 and IgG3, but also IgG2 and IgG4, subclass responses. Age, site, previous malaria episodes, and baseline characteristics including antibodies to CSP and other antigens reflecting malaria exposure and maternal IgGs, nutritional status, and hemoglobin concentration, significantly affected vaccine immunogenicity. We identified distinct signatures of malaria protection and risk in RTS,S/AS01E but not in comparator vaccinees. IgG2 and IgG4 responses to RTS,S antigens post-vaccination, and anti-CSP and anti-P. falciparum antibody levels pre-vaccination, were associated with malaria risk over 1-year follow-up. In contrast, antibody responses to HBsAg (all isotypes, subclasses, and timepoints) and post-vaccination IgG1 and IgG3 to CSP C-terminus and NANP were associated with protection. Age and site affected the relative contribution of responses in the correlates identified. CONCLUSIONS: Cytophilic IgG responses to the C-terminal and NANP repeat regions of CSP and anti-HBsAg antibodies induced by RTS,S/AS01E vaccination were associated with malaria protection. In contrast, higher malaria exposure at baseline and non-cytophilic IgG responses to CSP were associated with disease risk. Data provide new correlates of vaccine success and failure in African children and reveal key insights into the mode of action that can guide development of more efficacious next-generation vaccines. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12916-018-1186-4) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6208122 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-62081222018-11-16 Baseline exposure, antibody subclass, and hepatitis B response differentially affect malaria protective immunity following RTS,S/AS01E vaccination in African children Ubillos, Itziar Ayestaran, Aintzane Nhabomba, Augusto J Dosoo, David Vidal, Marta Jiménez, Alfons Jairoce, Chenjerai Sanz, Hèctor Aguilar, Ruth Williams, Nana Aba Díez-Padrisa, Núria Mpina, Maximilian Sorgho, Hermann Agnandji, Selidji Todagbe Kariuki, Simon Mordmüller, Benjamin Daubenberger, Claudia Asante, Kwaku Poku Owusu-Agyei, Seth Sacarlal, Jahit Aide, Pedro Aponte, John J Dutta, Sheetij Gyan, Ben Campo, Joseph J Valim, Clarissa Moncunill, Gemma Dobaño, Carlota BMC Med Research Article BACKGROUND: The RTS,S/AS01E vaccine provides partial protection against malaria in African children, but immune responses have only been partially characterized and do not reliably predict protective efficacy. We aimed to evaluate comprehensively the immunogenicity of the vaccine at peak response, the factors affecting it, and the antibodies associated with protection against clinical malaria in young African children participating in the multicenter phase 3 trial for licensure. METHODS: We measured total IgM, IgG, and IgG(1–4) subclass antibodies to three constructs of the Plasmodium falciparum circumsporozoite protein (CSP) and hepatitis B surface antigen (HBsAg) that are part of the RTS,S vaccine, by quantitative suspension array technology. Plasma and serum samples were analyzed in 195 infants and children from two sites in Ghana (Kintampo) and Mozambique (Manhiça) with different transmission intensities using a case-control study design. We applied regression models and machine learning techniques to analyze immunogenicity, correlates of protection, and factors affecting them. RESULTS: RTS,S/AS01E induced IgM and IgG, predominantly IgG1 and IgG3, but also IgG2 and IgG4, subclass responses. Age, site, previous malaria episodes, and baseline characteristics including antibodies to CSP and other antigens reflecting malaria exposure and maternal IgGs, nutritional status, and hemoglobin concentration, significantly affected vaccine immunogenicity. We identified distinct signatures of malaria protection and risk in RTS,S/AS01E but not in comparator vaccinees. IgG2 and IgG4 responses to RTS,S antigens post-vaccination, and anti-CSP and anti-P. falciparum antibody levels pre-vaccination, were associated with malaria risk over 1-year follow-up. In contrast, antibody responses to HBsAg (all isotypes, subclasses, and timepoints) and post-vaccination IgG1 and IgG3 to CSP C-terminus and NANP were associated with protection. Age and site affected the relative contribution of responses in the correlates identified. CONCLUSIONS: Cytophilic IgG responses to the C-terminal and NANP repeat regions of CSP and anti-HBsAg antibodies induced by RTS,S/AS01E vaccination were associated with malaria protection. In contrast, higher malaria exposure at baseline and non-cytophilic IgG responses to CSP were associated with disease risk. Data provide new correlates of vaccine success and failure in African children and reveal key insights into the mode of action that can guide development of more efficacious next-generation vaccines. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12916-018-1186-4) contains supplementary material, which is available to authorized users. BioMed Central 2018-10-31 /pmc/articles/PMC6208122/ /pubmed/30376866 http://dx.doi.org/10.1186/s12916-018-1186-4 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Ubillos, Itziar Ayestaran, Aintzane Nhabomba, Augusto J Dosoo, David Vidal, Marta Jiménez, Alfons Jairoce, Chenjerai Sanz, Hèctor Aguilar, Ruth Williams, Nana Aba Díez-Padrisa, Núria Mpina, Maximilian Sorgho, Hermann Agnandji, Selidji Todagbe Kariuki, Simon Mordmüller, Benjamin Daubenberger, Claudia Asante, Kwaku Poku Owusu-Agyei, Seth Sacarlal, Jahit Aide, Pedro Aponte, John J Dutta, Sheetij Gyan, Ben Campo, Joseph J Valim, Clarissa Moncunill, Gemma Dobaño, Carlota Baseline exposure, antibody subclass, and hepatitis B response differentially affect malaria protective immunity following RTS,S/AS01E vaccination in African children |
title | Baseline exposure, antibody subclass, and hepatitis B response differentially affect malaria protective immunity following RTS,S/AS01E vaccination in African children |
title_full | Baseline exposure, antibody subclass, and hepatitis B response differentially affect malaria protective immunity following RTS,S/AS01E vaccination in African children |
title_fullStr | Baseline exposure, antibody subclass, and hepatitis B response differentially affect malaria protective immunity following RTS,S/AS01E vaccination in African children |
title_full_unstemmed | Baseline exposure, antibody subclass, and hepatitis B response differentially affect malaria protective immunity following RTS,S/AS01E vaccination in African children |
title_short | Baseline exposure, antibody subclass, and hepatitis B response differentially affect malaria protective immunity following RTS,S/AS01E vaccination in African children |
title_sort | baseline exposure, antibody subclass, and hepatitis b response differentially affect malaria protective immunity following rts,s/as01e vaccination in african children |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6208122/ https://www.ncbi.nlm.nih.gov/pubmed/30376866 http://dx.doi.org/10.1186/s12916-018-1186-4 |
work_keys_str_mv | AT ubillositziar baselineexposureantibodysubclassandhepatitisbresponsedifferentiallyaffectmalariaprotectiveimmunityfollowingrtssas01evaccinationinafricanchildren AT ayestaranaintzane baselineexposureantibodysubclassandhepatitisbresponsedifferentiallyaffectmalariaprotectiveimmunityfollowingrtssas01evaccinationinafricanchildren AT nhabombaaugustoj baselineexposureantibodysubclassandhepatitisbresponsedifferentiallyaffectmalariaprotectiveimmunityfollowingrtssas01evaccinationinafricanchildren AT dosoodavid baselineexposureantibodysubclassandhepatitisbresponsedifferentiallyaffectmalariaprotectiveimmunityfollowingrtssas01evaccinationinafricanchildren AT vidalmarta baselineexposureantibodysubclassandhepatitisbresponsedifferentiallyaffectmalariaprotectiveimmunityfollowingrtssas01evaccinationinafricanchildren AT jimenezalfons baselineexposureantibodysubclassandhepatitisbresponsedifferentiallyaffectmalariaprotectiveimmunityfollowingrtssas01evaccinationinafricanchildren AT jairocechenjerai baselineexposureantibodysubclassandhepatitisbresponsedifferentiallyaffectmalariaprotectiveimmunityfollowingrtssas01evaccinationinafricanchildren AT sanzhector baselineexposureantibodysubclassandhepatitisbresponsedifferentiallyaffectmalariaprotectiveimmunityfollowingrtssas01evaccinationinafricanchildren AT aguilarruth baselineexposureantibodysubclassandhepatitisbresponsedifferentiallyaffectmalariaprotectiveimmunityfollowingrtssas01evaccinationinafricanchildren AT williamsnanaaba baselineexposureantibodysubclassandhepatitisbresponsedifferentiallyaffectmalariaprotectiveimmunityfollowingrtssas01evaccinationinafricanchildren AT diezpadrisanuria baselineexposureantibodysubclassandhepatitisbresponsedifferentiallyaffectmalariaprotectiveimmunityfollowingrtssas01evaccinationinafricanchildren AT mpinamaximilian baselineexposureantibodysubclassandhepatitisbresponsedifferentiallyaffectmalariaprotectiveimmunityfollowingrtssas01evaccinationinafricanchildren AT sorghohermann baselineexposureantibodysubclassandhepatitisbresponsedifferentiallyaffectmalariaprotectiveimmunityfollowingrtssas01evaccinationinafricanchildren AT agnandjiselidjitodagbe baselineexposureantibodysubclassandhepatitisbresponsedifferentiallyaffectmalariaprotectiveimmunityfollowingrtssas01evaccinationinafricanchildren AT kariukisimon baselineexposureantibodysubclassandhepatitisbresponsedifferentiallyaffectmalariaprotectiveimmunityfollowingrtssas01evaccinationinafricanchildren AT mordmullerbenjamin baselineexposureantibodysubclassandhepatitisbresponsedifferentiallyaffectmalariaprotectiveimmunityfollowingrtssas01evaccinationinafricanchildren AT daubenbergerclaudia baselineexposureantibodysubclassandhepatitisbresponsedifferentiallyaffectmalariaprotectiveimmunityfollowingrtssas01evaccinationinafricanchildren AT asantekwakupoku baselineexposureantibodysubclassandhepatitisbresponsedifferentiallyaffectmalariaprotectiveimmunityfollowingrtssas01evaccinationinafricanchildren AT owusuagyeiseth baselineexposureantibodysubclassandhepatitisbresponsedifferentiallyaffectmalariaprotectiveimmunityfollowingrtssas01evaccinationinafricanchildren AT sacarlaljahit baselineexposureantibodysubclassandhepatitisbresponsedifferentiallyaffectmalariaprotectiveimmunityfollowingrtssas01evaccinationinafricanchildren AT aidepedro baselineexposureantibodysubclassandhepatitisbresponsedifferentiallyaffectmalariaprotectiveimmunityfollowingrtssas01evaccinationinafricanchildren AT apontejohnj baselineexposureantibodysubclassandhepatitisbresponsedifferentiallyaffectmalariaprotectiveimmunityfollowingrtssas01evaccinationinafricanchildren AT duttasheetij baselineexposureantibodysubclassandhepatitisbresponsedifferentiallyaffectmalariaprotectiveimmunityfollowingrtssas01evaccinationinafricanchildren AT gyanben baselineexposureantibodysubclassandhepatitisbresponsedifferentiallyaffectmalariaprotectiveimmunityfollowingrtssas01evaccinationinafricanchildren AT campojosephj baselineexposureantibodysubclassandhepatitisbresponsedifferentiallyaffectmalariaprotectiveimmunityfollowingrtssas01evaccinationinafricanchildren AT valimclarissa baselineexposureantibodysubclassandhepatitisbresponsedifferentiallyaffectmalariaprotectiveimmunityfollowingrtssas01evaccinationinafricanchildren AT moncunillgemma baselineexposureantibodysubclassandhepatitisbresponsedifferentiallyaffectmalariaprotectiveimmunityfollowingrtssas01evaccinationinafricanchildren AT dobanocarlota baselineexposureantibodysubclassandhepatitisbresponsedifferentiallyaffectmalariaprotectiveimmunityfollowingrtssas01evaccinationinafricanchildren |